-- Updated PIONEER trial data in patients with indolent SM showed response rate of 60% for avapritinib versus 0% for placebo at 24 weeks, with response defined as ≥30% reduction in total symptom score --
-- Plan to present updated data from EXPLORER trial of avapritinib in patients with advanced SM at the European Hematology Association Virtual Congress on June 12 --
-- Initiated Phase 1 trial of next-generation KIT inhibitor BLU-263 in healthy volunteers --
PR Newswire
CAMBRIDGE, Mass., June 6, 2020